Skip to main content
OpenTrials
Active, Not Recruiting

NCT Number: NCT04467996

Minimum Effective Duration of Intrauterine Balloon Tamponade for the Management of Postpartum Hemorrhage

Intrauterine balloon tamponade (IUBT) is recommended worldwide as the second-line therapy to treat postpartum hemorrhage. While much literature demonstrates the effectiveness of this therapy, little is known about how long the IUBT should be used once placed. Though it is common to use IUBT for 12-24 hours, the balloon may be equally effective when used for shorter durations of time, which could have beneficial effects for patients and hospitals. The proposed study is a pragmatic randomized controlled trial of non-inferiority comparing two durations of time for intrauterine balloon tamponade placement, 6 and 18 hours, in controlling postpartum hemorrhage.

The specific aims of the proposed study are to determine: 1) whether quantitative blood loss significantly differs when the balloon is removed in 6 hours compared to 18 hours, 2) whether hemorrhage-related morbidity differs when the IUBT is kept in place for 6 or 18 hours, and 3) whether shorter duration of IUBT placement has beneficial effects including shortened postpartum hospital stays, improved maternal-infant bonding, and reduced postpartum pain prior to maternal discharge from hospital.

We hypothesize that, once hemorrhage control has been achieved with IUBT placement, there is no clinically significant difference in postpartum blood loss when the balloon is removed 6 hours after placement compared to 18 hours after placement.

Active, Not Recruiting

This study is active but is not currently recruiting participants.

Key information

Age range

18 year–55 year

Sex eligibility

Female

Study type

Interventional

Phase

Not applicable

Primary location

Denver Health Hospital

Denver, Colorado, 80204, United States

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Women at Denver Health and Hospital Authority (DHHA) who have an IUBT placed for postpartum hemorrhage due to uterine atony will be approached for enrollment in the study.

Exclusion criteria

  • Women will be excluded from the study if they: are less than 18 years of age; had a cesarean delivery; are unable to consent for themselves; have a preexisting or acquired clotting factor disorder such as von Willebrand or hemophilia, disseminated intravascular coagulation, or therapeutic anticoagulation at time of delivery; would refuse blood product transfusion; have a fetal demise or birth of a previable fetus; or are incarcerated at the time of delivery. Women who do not speak English or Spanish will be offered enrollment if a phone interpreter is available to review the consent, but will be excluded from the survey portion of the study.

Treatment and study plan

Intrauterine balloon tamponade

Device

Intrauterine balloon will be placed in the uterus for postpartum hemorrhage control.

Primary outcomes

  1. Quantitative blood loss

    Time frame: 18 hours

    total blood loss includes output from the intrauterine balloon plus blood loss from sanitary pads

Secondary outcomes

  1. Postpartum hemorrhage related outcomes

    Time frame: during admission

    return to the OR, replacement of the IUBT, hysterectomy, pelvic artery embolization

  2. Hematocrit

    Time frame: during admission

    change in hematocrit from admission to discharge

  3. Postpartum length of stay

    Time frame: during admission

    Length of stay in hours

  4. Endometritis

    Time frame: during admission

    diagnosed postpartum

  5. Chorioamnionitis

    Time frame: during admission

    requiring more than one dose of antibiotics postpartum

  6. Transfusion of packed red blood cells

    Time frame: during admission

    after IUBT placement

  7. Maternal-infant bonding

    Time frame: during admission

    measured by the mother-to-infant bonding scale (MIBS), scale 0-27, higher score indicates worse maternal-infant bonding

  8. Maternal pain

    Time frame: during admission

    measured by the visual analogue scale (VAS), scale 0-10, higher score indicates worse pain

Sponsors and collaborators

Lead sponsor

Denver Health and Hospital Authority

Other

Registry information

Official study title

Evaluation of the Minimum Effective Duration of Intrauterine Balloon Tamponade for the Management of Postpartum Hemorrhage: A Randomized Controlled Trial

Important dates

Study start
2020
Primary completion
2023
Study completion
2026
First posted
Jul 13, 2020
Registry last updated
Nov 21, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.